

# Taking on Typhoid: Eliminating Typhoid Fever as a Global Health Problem

Jessie Chen, Jessica E. Long,<sup>✉</sup> Kirsten Vannice, Tanya Shewchuk, Supriya Kumar, A. Duncan Steele, and Anita K. M. Zaidi

Enteric and Diarrheal Diseases, Global Health, Bill & Melinda Gates Foundation, Seattle, Washington, USA

Typhoid fever is a significant global health problem that impacts people living in areas without access to clean water and sanitation. However, collaborative international partnerships and new research have improved both knowledge of the burden in countries with endemic disease and the tools for improved surveillance, including environmental surveillance. Two typhoid conjugate vaccines (TCVs) have achieved World Health Organization prequalification, with several more in the development pipeline. Despite hurdles posed by the coronavirus disease 2019 pandemic, multiple TCV efficacy trials have been conducted in high-burden countries, and data indicate that TCVs provide a high degree of protection from typhoid fever, are safe to use in young children, provide lasting protection, and have the potential to combat typhoid antimicrobial resistance. Now is the time to double down on typhoid control and elimination by sustaining progress made through water, sanitation, and hygiene improvements and accelerating TCV introduction in high-burden locations.

**Keywords.** elimination; typhoid; typhoid conjugate vaccines.

Typhoid, caused by *Salmonella enterica* serovar Typhi, is a neglected disease that affects the most vulnerable populations, including those without access to safe water, improved sanitation, and hygiene (WASH) infrastructure. In 2019 alone, typhoid caused an estimated 110 000 deaths and 8.1 million disability-adjusted life-years (DALYs) [1]. However, modeling and meta-analyses suggest that these numbers have steadily declined over the past decade as access to WASH infrastructure and medical care in some geographies has improved, decreasing from an estimated 140 000 deaths and 10.3 million DALYs in 2010. There is further cause for optimism as well; over the past few years, there have been significant developments in both our understanding of disease burden through enhanced surveillance efforts and the development of typhoid conjugate vaccines (TCVs) with robust efficacy and effectiveness data. Additionally, we now have novel tools to further refine our understanding of burden in low- and lower-middle-income countries (LMICs) and to assess progress against typhoid burden [1, 2].

The typhoid vaccine development pipeline has experienced robust progress. There are currently 2 World Health Organization (WHO)-prequalified TCVs, with more products expected to enter the market in the next 1–2 years. TCV clinical

protection has been demonstrated in diverse settings, and vaccine introduction in several countries has been achieved due to an energized global public health ecosystem with collaborative manufacturers, enabling partnerships with the Typhoid Vaccine Acceleration Consortium (TyVAC) [3] and the Coalition against Typhoid (CaT) [4], supportive WHO policy and the 2017 recommendation for programmatic TCV use [5], Gavi funding [6], and engaged country partners.

However, it is well recognized that routine immunization programs have experienced unprecedented setbacks due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, resulting in childhood vaccination coverage experiencing the largest decrease in ~30 years [7, 8]. The WHO has recommended that TCV be deployed through the routine schedule, typically at 9 months, and there have been concerns that its introduction would be hampered due to these circumstances. Nevertheless, although coronavirus disease 2019 (COVID-19) prioritization and COVID-related disruptions initially presented challenges to the vaccine's rollout, the ecosystem of partners has successfully supported smoother and more rapid TCV decision-making and introduction than expected [9]. In less than a year after the first TCV received WHO prequalification, it was deployed for outbreak response in Pakistan and subsequently introduced into Pakistan's routine immunization program. Several other countries in Africa and Asia have followed suit, and many more are currently gathering evidence and assessing priorities for the decision-making process and Gavi application.

Although the relative prioritization of typhoid immunization fluctuates in countries' public health agendas, ongoing surveillance studies show that typhoid continues to substantially

Correspondence: Jessica Long, PhD MPH, 500 5th Ave N, Seattle, WA 98109 ([jessica.long@gatesfoundation.org](mailto:jessica.long@gatesfoundation.org)).

Open Forum Infectious Diseases®

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  
<https://doi.org/10.1093/ofid/ofad055>

contribute to morbidity in LMICs. Thanks to many efforts, today we have the tools to address this disease of the most vulnerable and impoverished communities. Now is the time for the global health community to double down on TCV vaccination efforts while maintaining momentum for improved access to WASH. This paper lays out the current estimated typhoid burden, surveillance efforts in place, new data on TCVs, recent and upcoming national introductions, and the reasons for optimism in the global efforts toward typhoid control.

## BURDEN

Typhoid burden has historically been difficult to measure, largely due to the necessity for blood culture for laboratory diagnosis and the paucity of other reliable laboratory tests for appropriate confirmation. Previous estimates of global burden have relied on extrapolation from a limited set of studies [10], but recent investments in regional surveillance have provided more accurate estimates of incidence and mortality, particularly in many African and South Asian countries. As previously outlined [11], there have been several surveillance studies in recent years in areas thought to have endemic typhoid: the Typhoid Fever Surveillance in Africa Program (TSAP) from 2010 to 2014 [12], Severe Typhoid Fever Surveillance in Africa (SETA) established from 2016 [13, 14], the Surveillance for Enteric Fever in Asia Project (SEAP) from 2016 to 2019 [15], Surveillance of Enteric Fever in India (SEFI) [16, 17], and the Wellcome Trust-funded Strategic Typhoid Alliance Across Africa and Asia (STRATAA) [16, 17]. These studies have contributed to a better understanding of the high burden in Asia and revealed that contrary to prior belief, typhoid is also a significant public health problem in many African settings. The latest Global Burden of Disease estimates show the largest typhoid burden in South Asia, Western Sub-Saharan Africa, and Eastern Sub-Saharan Africa, with 76 600, 10 000, and 8100 estimated deaths in 2019, respectively [1]. Estimated typhoid incidence rates show a similar geographic pattern (Figure 1). However, there is considerable year-to-year variation shown between studies, and the inconsistencies in methodologies used to estimate incidence underscore the need for further primary data collection and standardization of incidence rate calculation [2]. Children aged 5–14 years bear a significant portion of typhoid-related morbidity and mortality (with an estimated 46 800 deaths in 2019), so studies including this population are key [1].


High disease burden is one of the most important factors impacting a country's decision to introduce a particular vaccine. The availability of typhoid burden data from surveillance studies and concerns about high rates of antimicrobial resistance (AMR) enabled the WHO Strategic Advisory Group of Experts (SAGE) on Immunizations decision to recommend programmatic TCV use, prioritizing countries with the highest

overall burden or AMR threat [5]. Local vaccination strategies are still recommended to be formed with the local typhoid epidemiology and surveillance data quality in mind. Unfortunately, the absence of blood culture capacity in many typhoid-endemic regions means that disease burden remains poorly understood, both regionally and nationally [18]. It is therefore critical that countries and organizations with surveillance capacity continue to monitor typhoid burden and that new tools and approaches be made available to support typhoid burden estimation in those areas that currently have little awareness of burden.

## New Tools to Evaluate Typhoid Burden

In countries or subnational regions where blood culture capacity is lacking, prevalence of *S. Typhi* in the environment, specifically in sewage or environmental water contaminated with human fecal matter such as open drains or rivers, could provide a clue about typhoid infections in the population. Environmental surveillance (ES) methods have been developed for typhoid surveillance and are being validated in the field in Malawi, India, and Ghana [19], as well as in Fiji and Nigeria. ES for typhoid is expected to enable an estimation of whether a location that lacks blood culture has high, medium, or low burden of typhoid. Put together with data on the prevalence of *Salmonella*-associated intestinal perforations in the population and modeled estimates of typhoid burden based on neighboring countries and regions, such data are expected to contribute to an economic rationale to aid decision-making for TCV introduction [20]. Environmental samples enable surveillance of many thousands of people, making it cost-effective compared with individual-level testing [21]. Yet the methods are constrained to areas with confluent wastewater or drainage networks and less applicable in sparsely populated areas. Nonetheless, ES has been used to inform vaccine use against polio [22, 23] and estimate vaccine impact [24] of inactivated poliovirus vaccine. SARS-CoV-2 ES has been used to inform nonpharmaceutical interventions such as geographically targeted increases in access to clinical testing (see case studies in [25]) and to detect emerging variants [26, 27].

Additionally, novel methods in serosurveillance can provide enteric fever seroincidence estimates in countries lacking blood culture-based disease incidence estimates (see [28–30] for further details). The tool is based on an enzyme-linked immunosorbent assay that detects antibodies to *Salmonella*-specific hemolysin E antigen and has been validated with dried blood spots, which are easier to collect and store than serum samples [28]. Planning a population-representative serosurvey is often a challenging undertaking, but countries may plan to leverage stored samples from recently conducted serosurveys that were aimed at gauging prevalence of antibodies to SARS-CoV-2. If access to reagents, equipment, and training for the tool can be provided, seroincidence may provide a



**Figure 1.** IHME estimated incidence of typhoid in 2019 and TCV introduction status as of April 2023 [1] (PATH representatives, email communication, April 28, 2023). Abbreviations: IHME, Institute for Health Metrics and Evaluation; TCV, typhoid conjugate vaccine.

way forward for countries to generate additional evidence for TCV introduction decision-making.

WHO guidelines for polio ES to supplement poliovirus surveillance and to inform catch-up vaccine campaigns [31] and use of seroprevalence data to inform hepatitis B vaccine introduction at birth [32] are available and may be models for the development of guidelines for the implementation and interpretation of typhoid ES and serosurveillance.

## NEW DATA ON TYPHOID CONJUGATE VACCINES

### Broadening Efficacy Data

Tremendous progress continues to be made generating policy-relevant data on TCV efficacy, immunogenicity, safety, durability, and co-administration with other vaccines. Typbar-TCV, a Vi-TT conjugate vaccine and the first TCV receiving WHO prequalification, was approved in 2018 using data from a controlled human infection model (CHIM) showing efficacy of 87.1% (95% CI, 47.2%–96.9%) against clinically relevant typhoid fever [33]. Since then, the TyVAC consortium and other partners have generated substantial data on the efficacy and effectiveness of Typbar-TCV through clinical trials and leveraging routine introductions. Before the pandemic, data from a 12-month interim analysis of a randomized clinical trial (RCT) in Nepal estimated vaccine efficacy at 81.6% (95% CI, 58.8%–91.8%;  $P < .001$ ) against *S. Typhi* bacteremia in children 9 months to 16 years [34]. These were the first available data on

the efficacy of the Vi-TT vaccine and showed comparability to the findings of the original CHIM study. Despite the enormous challenges presented by the COVID-19 pandemic, data from the full 2-year Nepal trial, as well as data from Pakistan, Bangladesh, India, and Malawi, have emerged (Table 1). The suite of studies in high-burden countries shows that TCVs have the potential to consistently achieve a high level of protection.

There have been several critical questions for TCVs, including the following: How well do they protect the youngest children? Are the vaccines safe? Can they be co-administered with other vaccines? What is the duration of protection? And is there any indirect protection? A study on Vi-TT from Bangladesh showed high-level protection for children  $\leq 2$  years, with no significant difference from older age groups [37]. Vi-TT can also be safely co-administered with childhood Expanded Programme on Immunization (EPI) vaccines usually administered at 9 months of age, without vaccine interference, lending support to TCV inclusion among routine immunization schedules [41, 42]. Given the potential of newer vaccines to be added to the childhood EPI schedule in various countries (eg human papilloma virus vaccine HPV) and malaria vaccines such as RTS, S), there may be future studies with expanded safety data. As for duration of protection, the data thus far support TCV use as a single-dose vaccine for at least 3 years [43], although there are immunological data suggesting that seroconversion may persist in at least a subset of vaccinated children up

**Table 1. New Evidence on Clinical Protection of Typbar-TCV**

Location	Study Type	Duration of Follow-up	Age Range Vaccinated	Vaccine Efficacy (95% CI), %
Nepal [35]	Ph3 RCT	24 mo	9 mo to 16 y	79 (62–89)
Malawi [36]	Ph3 RCT	24 mo	9 mo to 12 y	81 (64–90)
Bangladesh [37]	Cluster RCT	17 mo	9 mo to 16 y	85 (66–91)
Navi Mumbai, India [38]	Case-control	N/A	9 mo to 14 y	80 (53–92)
Hyderabad, Pakistan [39]	Cohort	24 mo	6 mo to 10 y	95 (93–96)
Karachi, Pakistan [40]	Case-control	N/A	6 mo to 15 y	72 (34–88)

Abbreviations: RCT, randomized controlled trial; TCV, typhoid conjugate vaccine.

to 7 years [44]. Further confirmation will be required to assess the necessity of a booster dose. Finally, the evidence for indirect protection by Vi-TT is very modest, but analysis has not been conducted on a study sufficiently powered to detect this [37].

### Second Prequalified Typhoid Conjugate Vaccine

TyphiBEV, a Vi-CRM<sub>197</sub> vaccine developed by Biological E, Ltd, India, received WHO prequalification in December 2020 based on safety and immunogenicity established in a phase 2/3 study [45]. TyphiBEV demonstrated noninferiority compared with Typbar-TCV after 42 days, and there were no differences in safety profiles between the 2 vaccines [46]. Currently a phase 4 clinical trial is ongoing to examine the impact of TyphiBEV introduction in South India (VEVACT, NCT05500482). Additional studies of vaccine effectiveness are anticipated as the vaccine is introduced in routine programs.

There is a robust development pipeline that includes 2 TCVs, SK Bioscience's and PT Bio Farma's Vi-DT (diphtheria toxoid) vaccines. Both have recently achieved national licensure and are pursuing WHO prequalification, and phase 3 data from SK Bioscience's Vi-DT shows noninferiority to Vi-TT for safety as well as immunogenicity. There are also other TCV candidates at earlier stages of development [47]. Having multiple TCV vaccines reaching WHO prequalification allows for increased security in vaccine supply and availability and contributes to a "healthy market" as defined by Gavi, The Vaccine Alliance.


### TCV INTRODUCTIONS

Despite the COVID-19 pandemic, there has been significant progress in introducing TCVs (Figure 1). In Asia, Pakistan led the way by being the first country to incorporate TCV into the national immunization schedule in 2019 after initial targeted use in an outbreak setting against an extensively drug-resistant (XDR) strain of *S. Typhi* [39], and the scaled introduction was recently completed, reaching millions of children nationwide [48]. In 2021, Samoa held a mass vaccination campaign and became the first non-Gavi country to introduce TCV [49]. That same year, Liberia became the first African country to introduce TCV into its routine

immunization schedule using regional data of disease burden and limited clinical data [50]. It was followed shortly by Zimbabwe in 2021, also responding to a multidrug-resistant (MDR) outbreak of typhoid fever [51], and Nepal in April 2022 based on high disease burden [52]. Malawi has received approval from Gavi and is set to introduce TCV in the first half of 2023 [45].

There is accelerating momentum for national introductions in many other countries with multiple new National Immunization Technical Advisory Group (NITAG) recommendations in countries with a recognized burden of typhoid. The Indian NTAGI recommended TCV introduction in June 2022 [53], while the Bangladesh and Kenya NITAGs made similar recommendations and have applied to Gavi for vaccine subsidy support [54]. Several other countries across Asia and Africa are currently considering the introduction of TCV to their national immunization schedules. Vaccine effectiveness data from countries that have already introduced TCV, coupled with regional and modeling data and possibly novel surveillance tools, should provide more evidence for surrounding countries to consider implementation. Ongoing studies such as the Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGA) study [55] may provide information on TCV indirect effects in a locale with lower transmission intensity, in comparison with the modest effects observed in a high-density population in Bangladesh. As noted above, various data points have triggered decisions to introduce TCVs, including hospital data on typhoid perforations, disease modeling, emerging antimicrobial resistance [56], and cost-effectiveness information. While each country has a unique set of considerations, these resources, in addition to economic cost of illness studies [57, 58], provide a comprehensive set of data upon which countries considering new TCV introduction may draw.

The WHO has previously recognized that vaccines play a role in the battle against AMR, and in 2022 the WHO published an action framework that calls out the value of TCV to prevent infections and reduce antimicrobial use, specifically noting the estimated impact in Pakistan [59]. Recent work has also noted the potential of TCV to avert 342 000 deaths (95% prediction interval, 135 000–1.5 million) in Gavi-eligible countries [60]. Given the plethora of novel typhoid-related developments,



**Figure 2.** A roadmap for eliminating typhoid as a global health problem. Abbreviations: TCV, typhoid conjugate vaccine; WASH, safe water, improved sanitation, and hygiene.

the SAGE committee met in April 2022 to assess recent and upcoming data on typhoid burden and vaccines [61]. *S. Typhi* was recommended to be included as a pathogen of interest in future sessions on AMR, with the role of genomic studies to be assessed. SAGE reaffirmed existing recommendations on TCV use and noted data supportive of expansion of the age range of use up to 65 years, although official WHO guidelines for appropriate use up to age 45 remain in place, with catch-up campaigns advised up to 15 years due to disease burden and program feasibility in that age range [5]. At present, Gavi provides funding for routine immunization and catch-up campaigns up to 15 years of age. Population mobility is also recommended as a consideration for vaccination strategy formulation [61].

## MOVING FORWARD

### Areas of Further Research

The next phase of enhancing global control efforts is to drive sustained momentum for TCV use in endemic settings; with this in mind, a number of strategic areas of research are underway to provide the requisite data. First, as previously stated, more easily accessible data on disease burden at the local or regional level may help inform TCV rollout strategy and prioritization. New environmental surveillance methods being studied (outlined above in “New Tools to Evaluate Typhoid

Burden”) may provide a more detailed picture of local variations in disease burden. In cases where blood culture surveillance data are not available, pediatric surgical ward sentinel surveillance for cases of intestinal perforation in children, indicative of *Salmonella* infection [62], may be used as a proxy indicator of typhoid burden and assist countries in TCV introduction decision-making.

Second, more data are needed to confirm the impact of TCV on antimicrobial-resistant and XDR Typhi strains. Drug resistance is becoming an increasingly critical concern [63], and modeling studies suggest that introduction of TCV during routine immunization at age 9 months along with catch-up campaigns up to age 15 years can markedly reduce the impact of AMR typhoid [60]. Further empirical data will be useful in understanding the full potential of TCVs, particularly for prioritizing introductions to areas with high AMR. The ongoing Pakistan TCG Impact Study (ITRIPP) is aimed at understanding the impact of TCV on long-term transmission of AMR in Pakistan.

Finally, research into the feasibility of typhoid elimination is an ongoing area of study. Humans are the only known reservoir for *S. Typhi*, and the availability of effective tools in the form of vaccines, diagnostics, and environmental solutions such as sewage treatment and chlorination of drinking water together provide a possible means of eliminating typhoid. Current research is focused on ongoing efforts to improve surveillance and

diagnostic tools and focus on typhoid control in the immediate future.

### New Tools and Their Applications

Beyond TCVs, additional instruments are in development to support the goal of typhoid control. It is imperative that we use new environmental surveillance and serosurveillance tools effectively to ensure that countries have the evidence needed to make TCV introduction decisions in a timely manner. Gavi is assessing available surveillance tools and will be evaluating potential low-cost tools that can then be made available to countries to enable them to determine their typhoid burden. Gavi is also funding research to develop new diagnostics that will help guide clinical treatment. As progress is made toward typhoid control, chronic *S. Typhi* carriers will become an important focus of new development. Chronic infection occurs in 3%–5% of individuals following acute clinical or subclinical infection, and these carriers are likely causing new cases decades after infection [64]. Research in Chile is being conducted to improve identification of chronic carriers [65], and new methods of targeting treatment to these carriers will be critical to achieve typhoid elimination.

### Sustaining Momentum and Driving Impact

Given the success of TCV development, the primary focus moving forward is on sustained momentum for TCV use in endemic settings. Many partners in the typhoid control community, including Gavi, are aligned on the goals to accelerate TCV introduction and to ensure sufficient supply of low-cost, prequalified TCV from multiple manufacturers for delivery to Gavi-eligible countries and LMICs. Driving these milestones is the recognition that sustained impact will rely on generation of more data, documentation and communication of evidence, and a holistic view that incorporates other pathogen areas (Figure 2). While vaccines are an extremely important tool, we recognize that there is a broad range of interventions that are important to the ultimate success of typhoid control, including improved diagnostic tools and WASH infrastructure. There may also be novel, combination vaccines that can be developed, including a bivalent enteric fever vaccine to target both *S. Typhi* and *S. Paratyphi A*. Recognizing the changing landscape of climate change, increasing migration and urbanization, and the increasing MDR of *Salmonella* strains, there is a global public health imperative to accelerate our efforts toward the control of enteric fever.

### CONCLUSIONS

Important progress has been made in the fight against typhoid thanks to a strong partner ecosystem and country engagement that has seen reductions in burden in key regions, as well as advancements on many fronts. The WHO prequalification of 2 TCVs, with several more in the pipeline, provides an optimistic

picture for vaccine supply security in the future. TCVs have been introduced in 5 countries, and there is a growing number of countries that are anticipated to incorporate TCV into their routine immunization programs in the coming years. Building out surveillance to achieve wider geographical coverage of burden data and improved representation of rural areas will be crucial to inform future TCV introduction strategies, and new diagnostic tests will allow for improvements in both burden data and proper clinical management. Continued strong partnerships, both globally and at the country level, will underpin our ability to maintain momentum on what has been a neglected disease. The combined strategy of leveraging TCV while continuing to develop new tools will move us closer to achieving the goal of typhoid elimination as a global health problem.

### Acknowledgments

**Financial support.** No funding was received in support of this work.

**Supplement sponsorship.** This article appears as part of the supplement “Charting the Course to Meet the Challenges Ahead: Research and Developments on Typhoid and Other Invasive Salmonellosis” sponsored by the Coalition against Typhoid Secretariat, housed at the Sabin Vaccine Institute in Washington, DC and made possible by a grant from the Bill & Melinda Gates Foundation.

**Potential conflicts of interest.** All authors: no reported conflicts.

**Author contributions.** J.C., J.L., and S.K. drafted sections of the manuscript. J.C. and J.L. created figures and tables. K.V. and A.D.S. drafted the initial paper outline based off of A.Z.’s presentation on typhoid. T.S., K.V., S.K., A.D.S., and A.Z. provided detailed feedback and fact checking. J.C. and J.L. harmonized all feedback and edits.

**Patient consent.** This work does not include factors necessitating patient consent.

### References

1. GBD Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* **2020**; 396:1204–22.
2. Marchello CS, Hong CY, Crump JA. Global typhoid fever incidence: a systematic review and meta-analysis. *Clin Infect Dis* **2019**; 68:S105–16.
3. Jamka LP, Simiyu KW, Bentsi-Enchill AD, et al. Accelerating typhoid conjugate vaccine introduction: what can be learned from prior new vaccine introduction initiatives? *Clin Infect Dis* **2019**; 68:S171–6.
4. Lindsay S, Gellin B, Lee A, Garrett D. The coalition against typhoid: mobilizing a community for a global fight. *Clin Infect Dis* **2019**; 68:S161–4.
5. World Health Organization. Typhoid vaccines: WHO position paper—March 2018. *Wkly Epidemiol Rec* **2018**; 93:153–72.
6. Soble A, Patel Z, Sosler S, Hampton L, Johnson H. Gavi support for typhoid conjugate vaccines: moving from global investments to country introduction. *Clin Infect Dis* **2020**; 71:S160–4.
7. WHO, UNICEF. COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades. **2022**. Available at: <https://www.who.int/news/item/15-07-2022-covid-19-pandemic-fuels-largest-continued-backslide-in-vaccinations-in-three-decades>. Accessed October 25, 2022.
8. Guglielmi G. Pandemic drives largest drop in childhood vaccinations in 30 years. *Nature* **2022**; 608:253.
9. Walldorf JA. Early TCV introduction experiences. **2022**. Available at: [https://terrance.who.int/mediacentre/data/sage/SAGE\\_Slidedeck\\_Apr2022.pdf](https://terrance.who.int/mediacentre/data/sage/SAGE_Slidedeck_Apr2022.pdf). Accessed January 17, 2023.
10. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bull World Health Organ* **2004**; 82:346–53.
11. Carey ME, MacWright WR, Im J, et al. The Surveillance for Enteric Fever in Asia Project (SEAP), Severe Typhoid Fever Surveillance in Africa (SETA), Surveillance of Enteric Fever in India (SEFI), and Strategic Typhoid Alliance Across Africa and Asia (STRATAA) population-based enteric fever studies: a review of methodological similarities and differences. *Clin Infect Dis* **2020**; 71:S102–10.

12. Marks F, von Kalckreuth V, Aaby P, et al. Incidence of invasive *Salmonella* disease in Sub-Saharan Africa: a multicentre population-based surveillance study. *Lancet Glob Health* **2017**; 5:e310–23.
13. Park SE, Toy T, Cruz Espinoza LM, et al. The Severe Typhoid Fever in Africa program: study design and methodology to assess disease severity, host immunity, and carriage associated with invasive salmonellosis. *Clin Infect Dis* **2019**; 69: S422–34.
14. Marks F, Im J, Park SE, et al. The severe typhoid in Africa program: incidences of typhoid fever in Burkina Faso, Democratic Republic of Congo, Ethiopia, Ghana, Madagascar, and Nigeria. SSRN J 4292849 [Preprint]. December 7, 2022. Available at: <https://ssrn.com/abstract=4292849>. Accessed December 13, 2022.
15. Garrett DO, Longley AT, Aiemojy K, et al. Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia project. *Lancet Glob Health* **2022**; 10:e978–88.
16. Meiring JE, Shakya M, Khanam F, et al. Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. *Lancet Glob Health* **2021**; 9:e1688–96.
17. Phillips MT, Meiring JE, Voysey M, et al. A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance data. *Stat Med* **2021**; 40:5853–70.
18. Voysey M, Pant D, Shakya M, et al. Under-detection of blood culture-positive enteric fever cases: the impact of missing data and methods for adjusting incidence estimates. *PLoS Negl Trop Dis* **2020**; 14:e0007805.
19. Uzzell CB, Troman CM, Rigby J, et al. Environmental surveillance for *Salmonella* Typhi as a tool to estimate the incidence of typhoid fever in low-income populations. [version 1; peer review: awaiting peer review]. *Wellcome Open Res.* **2023**, 8:9.
20. Hagedorn BL, Gauld J, Feasey N, Hu H. Cost-effectiveness of using environmental surveillance to target the roll-out typhoid conjugate vaccine. *Vaccine* **2020**; 38: 1661–70.
21. Ngwira LG, Sharma B, Shrestha KB, et al. Cost of wastewater-based environmental surveillance for SARS-CoV-2: evidence from pilot sites in Blantyre, Malawi and Kathmandu, Nepal. *PLOS Glob Public Health* **2022**; 2:e0001377.
22. Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater—New York, June–August 2022. *MMWR Morb Mortal Wkly Rep* **2022**; 71:1065–8.
23. Brouwer AF, Eisenberg JNS, Pomeroy CD, et al. Epidemiology of the silent polio outbreak in Rahat, Israel, based on modeling of environmental surveillance data. *Proc Natl Acad Sci U S A* **2018**; 115:E10625–33.
24. Grassly NC, Wadood MZ, Safdar RM, Mahamud AS, Sutter RW. Effect of inactivated poliovirus vaccine campaigns, Pakistan, 2014–2017. *Emerging Infect Dis* **2018**; 24:2113–5.
25. World Health Organization. Environmental Surveillance for SARS-COV-2 to Complement Public Health Surveillance—Interim Guidance. World Health Organization; **2022**.
26. Levy JI, Andersen KG, Knight R, Karthikeyan S. Wastewater surveillance for public health. *Science* **2023**; 379:26–7.
27. Karthikeyan S, Levy JI, De Hoff P, et al. Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. *Nature* **2022**; 609:101–8.
28. Aiemojy K, Seidman JC, Saha S, et al. Estimating typhoid incidence from community-based serosurveys: a multicohort study. *Lancet Microbe* **2022**; 3: e578–87.
29. Aiemojy K, Rumunu J, Hassen JJ, et al. Seroincidence of enteric fever, Juba, South Sudan. *Emerg Infect Dis* **2022**; 28:2316–20.
30. Aiemojy K, Seidman JC, Charles R, Andrews JR. Seroepidemiology for enteric fever: emerging approaches and opportunities. *Open Forum Infect Dis* **2023**; 10(Suppl 1):S21–25.
31. Global Polio Eradication Initiative. *Field Guidance for the Implementation of Environmental Surveillance for Poliovirus*. World Health Organization; **2022**. Available at: <https://polioeradication.org/wp-content/uploads/2022/11/Field-Guidance-for-the-Implementation-of-ES-20221118-ENG.pdf>. Accessed December 15, 2022.
32. Expanded Programme on Immunization (EPI) of the Department of Immunization, Vaccines and Biologicals. *Preventing Perinatal Hepatitis B Virus Transmission: A Guide for Introducing and Strengthening Hepatitis B Birth Dose Vaccination*. World Health Organization, **2015**. Available at: [https://apps.who.int/iris/bitstream/handle/10665/208278/9789241509831\\_eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/208278/9789241509831_eng.pdf). Accessed December 16, 2022.
33. Jin C, Gibani MM, Moore M, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of *Salmonella* Typhi: a randomised controlled, phase 2b trial. *Lancet* **2017**; 390:2472–80.
34. Shakya M, Colin-Jones R, Theiss-Nyland K, et al. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. *N Engl J Med* **2019**; 381:2209–18.
35. Shakya M, Voysey M, Theiss-Nyland K, et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. *Lancet Glob Health* **2021**; 9:e1561–8.
36. Patel PD, Patel P, Liang Y, et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. *N Engl J Med* **2021**; 385:1104–15.
37. Qadri F, Khanam F, Liu X, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. *Lancet* **2021**; 398:675–84.
38. Date KA. Field effectiveness of a typhoid conjugate vaccine—Navi Mumbai (India), 2018–2020. Poster presented at: American Society of Tropical Medicine and Hygiene 69th Annual Meeting; November 18, 2020.
39. Yousafzai MT, Karim S, Qureshi S, et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed *Salmonella enterica* serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. *Lancet Glob Health* **2021**; 9:e1154–62.
40. Batool R, Tahir Yousafzai M, Qureshi S, et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: a case-control study. *Vaccine* **2021**; 39:5858–65.
41. Sirima SB, Ouedraogo A, Barry N, et al. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial. *Int J Infect Dis* **2021**; 108: 465–72.
42. Sirima SB, Ouedraogo A, Barry N, et al. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso. *Int J Infect Dis* **2021**; 102:517–23.
43. Patel P. Three year efficacy results from an individually randomized controlled double-blinded trial of a typhoid conjugate vaccine in Malawi. Poster presented at: American Society of Tropical Medicine and Hygiene 71st Annual Meeting, Seattle, WA, November 1, 2022.
44. Vadrevu KM, Raju D, Rani S, et al. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typhbar TCV\*) vaccine up to 7 years following primary vaccination of children <2 years of age with, or without, a booster vaccination. *Vaccine* **2021**; 39:6682–90.
45. Coalition Against Typhoid. Typhoid vaccines. Available at: <https://www.coalitionagainsttyphoid.org/the-issues/typhoid-vaccines/>. Accessed October 26, 2022.
46. Thuluvu S, Paradkar V, Matur R, Turaga K, Gv SR. A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator. *Hum Vaccin Immunother* **2022**; 18: 2043103.
47. Rai G K, Saluja T, Chaudhary S, et al. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. *Lancet Infect Dis* **2022**; 22:529–40.
48. Muhib F. Leading the way: Pakistan introduces typhoid conjugate vaccine. **2019**. Available at: <https://www.coalitionagainsttyphoid.org/leading-the-way-pakistan-introduces-typhoid-conjugate-vaccine/>. Accessed October 26, 2022.
49. Sikorski M. Amidst a global pandemic, Samoa rolls out TCV and other new vaccines. **2021**. Available at: <https://www.coalitionagainsttyphoid.org/amidst-a-global-pandemic-samoa-rolls-out-tcv-and-other-new-vaccines/>. Accessed October 26, 2022.
50. Clarke A. First in Africa: Liberia introduces typhoid conjugate vaccines. **2021**. Available at: <https://www.coalitionagainsttyphoid.org/first-in-africa-liberia-introduces-typhoid-conjugate-vaccines/>. Accessed October 26, 2022.
51. Chingwere M. Zim earns another WHO praise. *The Herald*. May 24, **2021**.
52. Gavi, the Vaccine Alliance. Nepal introduces typhoid vaccine into routine immunisation across the country. **2022**. Available at: <https://www.gavi.org/news/media-room/nepal-introduces-typhoid-vaccine-routine-immunisation-across-country>. Accessed October 26, 2022.
53. Dhawan V; Ministry of Family Health and Welfare. Minutes of the meeting of 17th National Technical Advisory Group on Immunization (NTAGI), held on 28th June 2022, under the Chairpersonship of Secretary (Health & Family Welfare) at Nirman Bhawan, New Delhi. **2022**. Available at: <https://main.mohfw.gov.in/sites/default/files/17th%20NTAGI%20Meeting%20Minutes%20June%2028%2C%202022.pdf>. Accessed October 26, 2022.
54. International Vaccine Access Center. View-hub by IVAC. Available at: <https://view-hub.org/map/?set=current-vaccine-intro-status&category=typhoid&group=vaccine-introduction>. Accessed November 2, 2022.

55. Haselbeck AH, Tadesse BT, Park J, et al. Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) using a cluster-randomized controlled phase IV trial: trial design and population baseline characteristics. *Vaccines (Basel)* **2021**; 9:281.
56. Saha SK, Tabassum N, Saha S. Typhoid conjugate vaccine: an urgent tool to combat typhoid and tackle antimicrobial resistance. *J Infect Dis* **2021**; 224:S788–91.
57. Riewpaiboon A, Piatti M, Ley B, et al. Cost of illness due to typhoid fever in Pemba, Zanzibar, East Africa. *J Health Popul Nutr* **2014**; 32:377–85.
58. Limani F, Smith C, Wachepa R, et al. Estimating the economic burden of typhoid in children and adults in Blantyre, Malawi: a costing cohort study. *PLoS One* **2022**; 17:e0277419.
59. WHO. Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: An Action Framework. World Health Organization; **2020**.
60. Birger R, Antillón M, Bilcke J, et al. Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. *Lancet Infect Dis* **2022**; 22:679–91.
61. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations. *Wkly Epidemiol Rec* **2022**; 97:261–76.
62. Birkhold M, Coulibaly Y, Coulibaly O, et al. Morbidity and mortality of typhoid intestinal perforation among children in Sub-Saharan Africa 1995–2019: a scoping review. *World J Surg* **2020**; 44:2892–902.
63. Nampota-Nkomba N, Carey M, Jamka L, Fecteau N, Neuzil K. Using typhoid conjugate vaccines to prevent disease, promote health equity, and counter drug-resistant typhoid fever. *Open Forum Infect Dis* **2023**; 10(Suppl 1): S6–12.
64. Maes M, Sikorski MJ, Carey ME, et al. Whole genome sequence analysis of *Salmonella* Typhi provides evidence of phylogenetic linkage between cases of typhoid fever in Santiago, Chile in the 1980s and 2010–2016. *PLoS Negl Trop Dis* **2022**; 16:e0010178.
65. Higginson EE, Nkeze J, Permala-Booth J, et al. Detection of *Salmonella* Typhi in bile by quantitative real-time PCR. *Microbiol Spectr* **2022**; 10:e0024922.